ANI Pharmaceutical’s ILUVIEN Study Shows Promise In Diabetic Macular Edema But Raises Safety Considerations In Phase 4 NEW DAY Trial

ANI Pharmaceuticals, Inc. has announced the publication of results from the Phase 4 NEW DAY clinical trial evaluating ILUVIEN® (fluocinolone acetonide intravitreal implant) in patients with diabetic macular edema (DME). The findings have been published in American Academy of Ophthalmology’s journal Ophthalmology, further validating data previously shared in 2025. ILUVIEN is indicated for DME patients who have already received corticosteroid treatment without experiencing significant increases in intraocular pressure.

The study, titled “Fluocinolone Acetonide Implant as a Baseline Therapy for Diabetic Macular Edema,” highlights the potential of ILUVIEN as an early treatment option. By delivering a sustained corticosteroid dose directly into the eye, the implant aims to manage inflammation and improve outcomes in patients with chronic DME, a leading cause of vision loss.

“We are proud that the results from the NEW DAY clinical trial have been published in Ophthalmology, a leading, globally respected peer-reviewed journal,” stated Nikhil Lalwani, President and Chief Executive Officer of ANI. “This publication represents our team’s continued commitment to generating clinical data for patients living with DME and for the overall retina community.”

However, the therapy carries important safety considerations. ILUVIEN is contraindicated in patients with certain infections, glaucoma, or hypersensitivity to its components. Known risks associated with intravitreal injections include eye inflammation, infection, retinal complications, and fluctuations in intraocular pressure. Long-term corticosteroid use may also increase the risk of glaucoma, cataracts, and delayed healing.

Clinical trial data showed that common ocular adverse events included cataracts, floaters, eye pain, and conjunctival hemorrhage, while non-ocular effects such as anemia, headache, and renal issues were also reported. A notable proportion of patients experienced elevated intraocular pressure, requiring medication or surgical intervention in some cases. Additionally, cataract formation was significantly higher in treated patients, with many requiring surgery within the study period.